Rabin Medical Center-Beilinson Campus Trials

Rabin Medical Center-Beilinson Campus	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Stemmer, Salomon

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed

571

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

10/24

LIVERATION, NCT05201404 / 2021-005286-41: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Recruiting

471

Europe, US, RoW

Namodenoson, CF102, Placebo, Inactive control

Can-Fite BioPharma, CanFite BioPharma Ltd.

Hepatocellular Carcinoma, Cirrhosis

02/25

10/25

CF102-222PC, NCT06387342: Namodenoson Treatment of Advanced Pancreatic Cancer

Recruiting

RoW

Namodenoson 25mg, CF102

Can-Fite BioPharma

Pancreatic Adenocarcinoma, Pancreatic Cancer

07/26

12/26

NCT04640246: Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Recruiting

1/2

US, RoW

TBX-3400

Taiga Biotechnologies, Inc.

Cancer, Tumor, Solid, Refractory Cancer

01/23

04/23

AM003-FIH-001, NCT06258330: Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

Completed

RoW

AM003

Aummune Ltd.

Solid Tumor

07/24

10/24

Gurion, Ronit

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting

733

Europe, US, RoW

Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred

Regeneron Pharmaceuticals

Follicular Lymphoma (FL)

07/29

NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting

2/3

501

Europe, US, RoW

Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)

Karyopharm Therapeutics Inc

Relapsed/refractory Diffuse Large B-cell Lymphoma

12/24

12/25

HLH, NCT05882175: Prospective Validation of the OHI Index

Recruiting

N/A

300

RoW

Meir Medical Center, Children's Hospital Medical Center, Cincinnati, Rabin Medical Center, Sheba Medical Center, Schneider Children's Medical Center, Israel

HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy, Hematologic Neoplasms

03/25

03/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Stemmer, Salomon

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed

571

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

10/24

LIVERATION, NCT05201404 / 2021-005286-41: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Recruiting

471

Europe, US, RoW

Namodenoson, CF102, Placebo, Inactive control

Can-Fite BioPharma, CanFite BioPharma Ltd.

Hepatocellular Carcinoma, Cirrhosis

02/25

10/25

CF102-222PC, NCT06387342: Namodenoson Treatment of Advanced Pancreatic Cancer

Recruiting

RoW

Namodenoson 25mg, CF102

Can-Fite BioPharma

Pancreatic Adenocarcinoma, Pancreatic Cancer

07/26

12/26

NCT04640246: Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Recruiting

1/2

US, RoW

TBX-3400

Taiga Biotechnologies, Inc.

Cancer, Tumor, Solid, Refractory Cancer

01/23

04/23

AM003-FIH-001, NCT06258330: Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

Completed

RoW

AM003

Aummune Ltd.

Solid Tumor

07/24

10/24

Gurion, Ronit

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

Recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

Recruiting

733

Europe, US, RoW

Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred

Regeneron Pharmaceuticals

Follicular Lymphoma (FL)

07/29

NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting

2/3

501

Europe, US, RoW

Karyopharm Therapeutics Inc

Relapsed/refractory Diffuse Large B-cell Lymphoma

12/24

12/25

HLH, NCT05882175: Prospective Validation of the OHI Index

Recruiting

N/A

300

RoW

Meir Medical Center, Children's Hospital Medical Center, Cincinnati, Rabin Medical Center, Sheba Medical Center, Schneider Children's Medical Center, Israel

HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy, Hematologic Neoplasms

03/25

03/26



	Diseases Companies Products Productz Mechanisms of Action Sites